Marianne Cohan, DDS, AAFE, AACD, has over 31 years of clinical experience diagnosing and treating oral health conditions, including dark spots on the lips and surrounding tissue
(2018) , there exists a notable amount of missing phenotypic data across publications, encompassing both non-motor symptoms and key motor features (Kasten et al
Over the past couple of years, as millions of Americans began taking these GLP-1s and as appetites have shrunk restaurants started to notice
Choosing Between Semaglutide and Tirzepatide for Microdosing From a pharmacology standpoint, semaglutide is a pure GLP-1 receptor agonist , while tirzepatide is a dual GIP/GLP-1 agonist that activates both GIP and GLP-1 receptors.[2,4] That dual mechanism likely contributes to tirzepatides strong weight-loss results at full doses compared with semaglutide in head-to-head and indirect comparisons.[2,7] In the context of microdosing: Some clinicians and patients feel that microdosing tirzepatide provides robust appetite control even at relatively low doses, though this is based largely on real-world experience rather than large trials
However, it remains important to consider that GLP-1 receptor agonists may be limited by unfavorable side effects, especially in the context of PD
Available in 10mg and 20mg total
